Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue

Activated factor X (FXa) is an important player in the coagulation cascade responsible for thrombin generation, which is activated during atrial fibrillation. Increasing evidence suggests that FXa influences cell signalling in various cell types by activating protease-activated receptors (PARS). It is so far not known if molecular effects of FXa affect atrial signal transduction. To study the effects of FXa, human atrial tissue slices were cultivated with EXa up to 24 h. Additionally, rapid pacing was applied at 4 Hz to resemble atrial fibrillation. The inhibitory impact of FXa antagonist (Rivaroxaban), protease-activated receptor 1 antagonist (SCH79797), and protease-activated receptor 2 antagonist (GB83) were analysed under experimental conditions. The exposure of atrial tissue to FXa resulted in the 1.7 fold upregulation of PAR2-mRNA, activation of MAP kinases (ERK1/2) and NF-kappa B signalling. Furthermore EXa increased the expression of adhesion molecule ICAM-1 (1.82 perpendicular to 0,20), chemokine IL-8 (1.94 perpendicular to 020), as well as prothrombotic molecule PAI-1 (1.52 +/- 0.17). The combination of rapid pacing and FXa caused significant upregulation of PAR1 (2.82 +/- 0.22), PAR2 (2.66 +/- 0.40), ICAM-1 (2,13 +/- 025). IL-8 (222 +/- 0.24), LOX-1 (2.59 +/- 0.35), and PAI-1 (2.65 +/- 0.52) at the mRNA level. Rivaroxaban and GB83 prevented upregulation of PARs, ICAM-1, LOX-1, IL-8, and activation of MAP kinases. The elevation in the expression of PAI-1 was hindered in the presence of SCH79797, or Rivaroxaban. The present study indicates that FXa mediates inflammatory signalling in atrial tissue. Importantly, FXa and tachyarrhythmia act synergistically to increase expression of protease-activated receptors and inflammatory mediators. Rivaroxaban prevented effectively FXa-induced molecular effects in human atrial tissue particularly during rapid pacing. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved,